Effect of acyclovir-melissa nanofiber patch in treatment of recurrent herpes labialis

Phase 3

• Conditions: Recurrent Herpes Labialis.; Herpesviral vesicular dermatitis; B00.1

• Registration Number: IRCT20141124020073N3
• Lead Sponsor: Esfahan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 8 March 2022

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

Maximum interval of 48 hours since the emergence of the lesion
Having a recurrent lesion (i.e., secondary)
Receiving no antiviral, anti-inflammatory, steroid, or analgesic drugs
Vesicular stage of the lesion and lesion size <1 cm

Exclusion Criteria

Allergies to the used herbal medicines
Hepatic, renal, or systemic diseases
Use of birth control pills
Breastfeeding

Study & Design

• Study Type: interventional
• Study Design: Not specified